CEO of Novo Nordisk is leaving, highlighting challenges in obesity market, company facing competition

From Morningstar: 2025-05-19 04:45:00

Novo Nordisk CEO Lars Fruergaard Jørgensen is stepping down, highlighting challenges in the obesity market. Former CEO Lars Rebien Sørensen will join the board. The company has faced share price increases and setbacks, facing competition from Eli Lilly. Leadership changes in the healthcare sector are increasing, driven by growth pressure and potential disruptions from US policy changes. Novo’s future growth depends on negotiations, FDA interactions, and market dynamics. Maintaining a fair value estimate of DKK 640/$89, Novo’s innovation and moat support its market position. The board may consider external candidates for the CEO position, prioritizing US market understanding.



Read more at Morningstar: Novo Nordisk: CEO’s Surprise Departure Points to…